UCB to Sell Established Brands in India to Dr. Reddy’s

Belgium's UCB has agreed to sell its established brands in India, including its franchises in the areas of allergies and respiratory disorders, to Dr. Reddy's Laboratories for INR 8 billion, about €118 million. Revenue of the acquired business for the 2014 calendar year is approximately INR 1.5 billion. About 350 members of staff will transfer from UCB to Dr. Reddy's.

Alok Sonig, senior vice president and India business head of Dr. Reddy's Laboratories, said: "The acquired UCB portfolio shall accelerate Dr. Reddy's presence in the high growth areas of dermatology, respiratory and paediatrics with market leading brands like Atarax, Nootropil, Zyrtec, Xyzal, Xyzal M, etc."

UCB said the move is in line with its strategy to "provide the best value for patients and to focus on bringing them innovative drugs while ensuring its mature brands portfolio continues to reach as many people as possible." Mark McDade, UCB's chief operating officer, said: "This position allows us to focus on our neurology portfolio in India, providing innovative solutions to patients living with severe diseases."

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.